Nuclera is a Bioprinter company that enables life science researchers to accelerate breakthrough improvements in human health through easy access of biomolecules. Co-founders Jiahao, Gordon, Radu and Michael founded Nuclera in 2013 during the first year of their PhDs at the University of Cambridge. Being scientists at heart, Nuclera believe that inaccessibility is the key bottleneck in biology.
Since then, Nuclera has made it their mission to solve biological inaccessibility. This drive feeds into their collective vision to make biology accessible to everyone through desktop bioprinting. They do this by providing tools designed by scientists for scientists.
Nuclera is now the pioneer in making biology accessible by combining its eProtein™ and eDNA™ bio-inks with eDrop™ digital microfluidics. The combination of these technologies into a desktop bioprinter creates an unprecedented one-stop shop ecosystem that enables their customers to streamline and program biology.
Innovate UK EDGE support for Nuclera was two-pronged: innovation and growth and international collaborations. Under innovation and growth support was provided to:
- Position product, the company and the value add correctly within the value chain.
- Create a commercialisation plan covering route(s) to market and Sales & Marketing strategy.
- Organisational assessment of the skills mix needed to successfully secure Series B funding.
- Prepare and communicate a convincing business case for a successful Series B fundraising round for US$42.7m in Feb 2022.
- Design a clear organisational structure to double headcount to 144 people by end-2022.
Support for international collaborations was offered through the Semiconductor Taiwan 2021 GBIP.
Nuclera has received Innovate UK grant funding of £100K to develop its bioprinter Proof of Concept in 2014 and £202.9K for Development of Prototype in 2015 through the Smart competitions.
